Group
VEGFR targeting TKI
Group Profile
| Therapeutic Class | Targeted Therapy |
| Drug Class | Tyrosine Kinase Inhibitors (TKIs) |
| Mechanism of Action | VEGFR1/2/3 inhibitor |
| Drugs in group | Tivozanib· Apatinib· Fruquintinib |
Study design
RT–Drug Timing Window
Study design
RT–Drug Timing Window
Radiobiological rationale for RT–drug interaction
Radiosensitizing chiefly via vascular normalization/endothelial killing; dose-dependent (Jiang et al., Cancer Medicine, 2023; Guelfi et al., Nature Reviews Cancer, 2024). As with other antiangiogenics, endothelial adverse effects are not tumor-restricted, providing a rationale for increased vascular normal-tissue injury (GI perforation/fistula, mucosal injury, and possible cerebral radionecrosis), especially at higher doses.
The data above refer to patients treated with VEGFR targeting TKI as the sole drug class,
excluding any concurrent use of drugs from other groups.
Combination therapy data are available in the section below.
Individual Drugs
Select a drug to view its individual evidence base (drug + SBRT, no other concurrent systemic drugs). Drugs without available data are shown greyed out.